Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2003

01-05-2003

Effects of Long-Term HRT and Tamoxifen on the Expression of Progesterone Receptors A and B in Breast Tissue from Surgically Postmenopausal Cynomolgus Macaques

Authors: E. Isaksson, H. Wang, L. Sahlin, B. von Schoultz, J.M. Cline, E. von Schoultz

Published in: Breast Cancer Research and Treatment | Issue 2/2003

Login to get access
Metadata
Title
Effects of Long-Term HRT and Tamoxifen on the Expression of Progesterone Receptors A and B in Breast Tissue from Surgically Postmenopausal Cynomolgus Macaques
Authors
E. Isaksson
H. Wang
L. Sahlin
B. von Schoultz
J.M. Cline
E. von Schoultz
Publication date
01-05-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1023925906199

Other articles of this Issue 2/2003

Breast Cancer Research and Treatment 2/2003 Go to the issue

OriginalPaper

Risk Factors for Colorectal Cancer Following Breast Cancer

OriginalPaper

Prolactin Overexpression by MDA-MB-435 Human Breast Cancer Cells Accelerates Tumor Growth

OriginalPaper

Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy

OriginalPaper

2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5,6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP)

OriginalPaper

Treatment of Early Stage Breast Cancer: do Surgeons and Patients Agree Regarding Whether Treatment Alternatives were Discussed?

OriginalPaper

Phosphocitrate Inhibits Calcium Hydroxyapatite Induced Mitogenesis and Upregulation of Matrix Metalloproteinase-1, Interleukin-1β and Cyclooxygenase-2 mRNA in Human Breast Cancer Cell Lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits